Core Insights - The company reported a total revenue of 41.559 million yuan, representing a year-on-year decrease of 5.2% [1] - Research and development expenses amounted to 143 million yuan, down 50.5% year-on-year [1] - The loss attributable to the parent company was 178 million yuan, a reduction of 52.2% compared to the previous year [1] - The loss per share was 0.43 yuan [1] Business Development - The company is focusing on the global promotion of the LuX-Valve series for transcatheter tricuspid valve replacement and the commercialization of the Ken-Valve for transcatheter aortic valve replacement [1][2] - The LuX-Valve series will be developed through global clinical trials, expanding business regions, and establishing international strategic partnerships to enhance its global technical advantage [2] - The Ken-Valve product has received approval from the National Medical Products Administration, and the company has initiated the registration process in multiple provinces and cities, along with educational and promotional activities in hospitals [2] - The company aims to achieve commercialization of the Ken-Valve by the first half of 2025 [2]